Forte Biosciences reports positive Phase 1b vitiligo data for FB102 with 29.6% mean FVASI improvement

Forte Biosciences reported positive Phase 1b vitiligo results showing FB102 achieved 29.6% mean FVASI improvement at week 24 (p=0.020).

Key Highlights:

• FB102 produced 29.6% mean FVASI improvement at week 24 vs 7.9% placebo in efficacy-evaluable population (p=0.020).
• Early response by Day 64 (p=0.023) with continued improvement through Week 24 after a 12-week treatment course.
• Subjects with baseline FVASI ≥0.75 saw 43.2% mean improvement at Week 24 (p=0.006); FVASI50 58.8%, FVASI75 23.5%.
• Responder rates: overall FVASI50 34.4% and FVASI75 12.5% for FB102 at Week 24; placebo responder noted in analysis.
• Safety profile favorable versus placebo: only mild-to-moderate AEs, no severe (Grade ≥3) events reported.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.